Chemotherapy Definitions and Policies for Thymic Malignancies

by Nicolas Girard, Rohit Lal, Heather Wakelee, Gregory J. Riely, Patrick J. Loehrer
Published 2014-02-01

Management of thymoma‐associated pure red cell aplasia: A novel use of blood substitute HBOC‐201 in a Jehovah’s Witness

by Maria M. Rubinstein, Cheryl Goss, Scott T. Avecilla, Gregory P. Dubé, Gregory J. Riely, Jodi V. Mones
Published 2020-02-01

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.

by William Pao, Vincent A Miller, Katerina A Politi, Gregory J Riely, Romel Somwar, Maureen F Zakowski, Mark G Kris, Harold Varmus
Published 2005-03-01

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.

by William Pao, Theresa Y Wang, Gregory J Riely, Vincent A Miller, Qiulu Pan, Marc Ladanyi, Maureen F Zakowski, Robert T Heelan, Mark G Kris, Harold E Varmus
Published 2005-01-01

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.

by Kathryn C Arbour, Jarushka Naidoo, Keith E Steele, Ai Ni, Andre L Moreira, Natasha Rekhtman, Paul B Robbins, Joyson Karakunnel, Andreas Rimner, James Huang, Gregory J Riely, Matthew D Hellmann
Published 2017-01-01